(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - 25 Bike Brands for Ordinary Use
- 3IDF kills four terrorists equipped with weapons, surveillance gear near Gaza's Yellow Line
- 4The Electric Bicycle Americans Can Confide in 2024
- 5Novo Nordisk cuts Wegovy price in South Africa for a second time
- Figure out how to Guarantee Your Dental Embeds Endure forever
- She loves to give experiences. He goes for sentimental gifts. They ask an expert: What is the perfect holiday present?
- Safeguarding Your Senior Protection Against Extortion and Tricks.
- Exploring ways to reduce the impact of space junk on Earth
- An Excursion Through Renowned Western Network programs
- At least 55 injured in Russia after train crashes, overturns
- Fundamental Home Exercise center Hardware: Amplify Your Exercises
- Iran war drives global fertilizer prices up, raising food cost fears
- The Specialty of Cleaning up: Change Your Space and Brain
